
News|Articles|January 19, 2015
Treatment With a Monocyte-Targeting Agent for Pancreatic Cancer
Author(s)Andrea Wang-Gillam, MD, PhD
Andrea Wang-Gillam, MD, PhD, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.
Advertisement
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.
More on this trial > >
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































